Literature DB >> 16194200

Cysteine-mutations in von Willebrand factor associated with increased clearance.

C J Schooten1, P Tjernberg, E Westein, V Terraube, G Castaman, J A Mourik, M J Hollestelle, H L Vos, R M Bertina, H M Berg, J C J Eikenboom, P J Lenting, C V Denis.   

Abstract

BACKGROUND: von Willebrand disease (VWD) is a bleeding disorder caused by the decrease of functional von Willebrand factor (VWF). Low levels of VWF can result from decreased synthesis, impaired secretion, increased clearance or combinations thereof. Several mutations lead to impaired synthesis or secretion of VWF, however, little is known about the survival of VWF in the circulation.
OBJECTIVES: To evaluate the effect of several VWF mutations on VWF clearance. PATIENTS/
METHODS: The effect of three cysteine-mutations (C1130F, C1149R or C2671Y) on the in vivo survival of VWF was studied in patients carrying these mutations and in a VWF-deficient mice model.
RESULTS: In patients carrying these mutations, we observed increased propeptide/mature VWF ratios and rapid disappearance of VWF from the circulation after desmopressin treatment. Detailed analysis of in vivo clearance of recombinant VWF in a VWF-deficient mice model revealed a fourfold increased clearance rate of the mutants. The mutations C1130F, C1149R and C2671Y are each associated with reduced survival of VWF in the circulation. Detailed analysis of the recombinant mutant VWF demonstrated that increased clearance was not due to increased proteolysis by ADAMTS-13. We did not identify functional or structural characteristics that the mutant proteins have in common and could be associated with the phenomenon of increased clearance.
CONCLUSIONS: Cysteine-mutations in VWF may result in reduced in vivo survival. The observation that various mutations are associated with increased in vivo clearance may have major implications for the therapeutic strategies that rely on the rise of endogenous VWF after desmopressin administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194200     DOI: 10.1111/j.1538-7836.2005.01571.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  21 in total

1.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene.

Authors:  Heidi L Lemmerhirt; Jordan A Shavit; Gallia G Levy; Suzanne M Cole; Jeffrey C Long; David Ginsburg
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

Review 2.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

3.  Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation.

Authors:  Jiong-Wei Wang; Dafna J Groeneveld; Guy Cosemans; Richard J Dirven; Karine M Valentijn; Jan Voorberg; Pieter H Reitsma; Jeroen Eikenboom
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

4.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

5.  Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.

Authors:  Jie Dong; Yan-Jun Li; Zhi-Kai Yang; Rong Xu
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

6.  Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

Authors:  A Gézsi; U Budde; I Deák; E Nagy; A Mohl; A Schlammadinger; Z Boda; T Masszi; J E Sadler; I Bodó
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

7.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

8.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

9.  Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami.

Authors:  T Obser; M Ledford-Kraemer; F Oyen; M A Brehm; C V Denis; R Marschalek; R R Montgomery; J E Sadler; S Schneppenheim; U Budde; R Schneppenheim
Journal:  J Thromb Haemost       Date:  2016-08-20       Impact factor: 5.824

10.  Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients.

Authors:  Kathelijn Fischer; Ronan Pendu; Carina J van Schooten; Karin van Dijk; Cécile V Denis; H Marijke van den Berg; Peter J Lenting
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.